8-K Announcements
6Material company update
Mar 5, 2026·SEC
Material company update
Dec 22, 2025·SEC
Material company update
Dec 15, 2025·SEC
Silence Therapeutics plc(SLN)Earnings, Financials & Key Ratios
SLN•NASDAQ
$7.36
$348M mkt cap·Price updated May 6, 2026
AboutSilence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase I clinical trials for the treatment of myelodysplastic syndrome; and SLN124 for the treatment of polycythemia vera. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company also has a collaboration with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.Show more
- Revenue$559K-98.7%
- EBITDA-$90M-43.1%
- Net Income-$89M-95.6%
- EPS (Diluted)-1.89+20.3%
- Gross Margin61.54%-15.4%
- EBITDA Margin-16055.99%-10972.8%
- Operating Margin-16055.99%-10869.1%
- Net Margin-15851.88%-15034.3%
- ROE-247.11%-325.4%
SLN Key Insights
Silence Therapeutics plc (SLN) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Sales declining 36.7% over 5 years
- ✗Shares diluted 100.0% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
SLN Price & Volume
Silence Therapeutics plc (SLN) stock price & volume — 10-year historical chart
Loading chart...
SLN Growth Metrics
Silence Therapeutics plc (SLN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-36.65%
3 Years-70.45%
TTM-98.66%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-188.53%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-161.73%
Return on Capital
10 Years-52.39%
5 Years-58.28%
3 Years-51.11%
Last Year-54.25%
SLN Recent Earnings
Silence Therapeutics plc (SLN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (64%)●Beat Revenue 4/12 qtrs (40%)
Q2 2026Latest
Mar 5, 2026EPS
$0.25
Est $0.32
+21.9%
Revenue
$39,000
Est $3M
-98.7%
Q4 2025
Nov 6, 2025EPS
$0.45
Est $0.40
-12.5%
Revenue
$159,000
Est $3M
-94.9%
Q3 2025
Aug 7, 2025EPS
$0.54
Est $0.27
-100.0%
Revenue
$224,000
Est $3M
-93.1%
Q2 2025
May 8, 2025EPS
$0.60
Est $0.18
-233.3%
Revenue
$142,000
Est $2M
-93.9%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 5, 2026 | $0.25vs $0.32+21.9% | $39,000vs $3M-98.7% |
| Q4 2025 | Nov 6, 2025 | $0.45vs $0.40-12.5% | $159,000vs $3M-94.9% |
| Q3 2025 | Aug 7, 2025 | $0.54vs $0.27-100.0% | $224,000vs $3M-93.1% |
| Q2 2025 | May 8, 2025 | $0.60vs $0.18-233.3% | $142,000vs $2M-93.9% |
Based on last 12 quarters of dataView full earnings history →
SLN Peer Comparison
Silence Therapeutics plc (SLN) competitors in RNA and Genome Editing Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ALNY | 40.43B | 303.00 | 130.04 | 65.19% | 13.46% | 98.29% | 1.62 | |
 ARWR | 11.08B | 79.14 | -6486.89 | 232.58% | 18.54% | 35.64% | 0.73 | |
 SRPT | 2.42B | 23.03 | -3.23 | 15.58% | 2.98% | 4.89% | 0.91 | |
 NTLA | 1.61B | 13.85 | -3.64 | -100% | -61.47% | 0.14 | ||
 IONS | 12.7B | 76.85 | -32.29 | 33.87% | -30.87% | -58.57% | 5.35 | |
 REGN | 74.89B | 720.78 | 17.38 | 0.99% | 29.65% | 14.32% | 0.09 | |
 MDGL | 12.38B | 539.73 | -42.00 | 432.05% | -27.32% | -50.15% | 0.59 | |
 AKRO | 4.5B | 54.65 | -14.57 | -30.58% | 0.05 |
Compare SLN vs Peers
Silence Therapeutics plc (SLN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SLN Income Statement
Silence Therapeutics plc (SLN) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 16K | 0 | 244K | 5.48M | 12.41M | 21.66M | 25.38M | 43.26M | 559K |
| Revenue Growth % | -97.92% | -100% | - | 2145.49% | 126.59% | 74.43% | 17.18% | 70.47% | -98.71% |
| Cost of Goods Sold | 7.94M | 9.74M | 0 | 3.76M | 7.46M | 13.46M | 10.32M | 11.81M | 215K |
| COGS % of Revenue | 49643.75% | - | - | 68.66% | 60.06% | 62.17% | 40.66% | 27.3% | 38.46% |
| Gross Profit | -7.93M▲ 0% | -9.74M▼ 22.9% | 244K▲ 102.5% | 1.72M▲ 603.7% | 4.96M▲ 188.8% | 8.19M▲ 65.2% | 15.06M▲ 83.8% | 31.45M▲ 108.9% | 344K▼ 98.9% |
| Gross Margin % | -49543.75% | - | 100% | 31.34% | 39.94% | 37.83% | 59.34% | 72.7% | 61.54% |
| Gross Profit Growth % | 0.18% | -22.91% | 102.5% | 603.69% | 188.82% | 65.19% | 83.8% | 108.86% | -98.91% |
| Operating Expenses | 14.41M | 20.57M | 22.98M | 37.56M | 50.77M | 69.23M | 64.66M | 94.77M | 90.1M |
| OpEx % of Revenue | 90043.75% | - | 9417.21% | 685.6% | 408.96% | 319.7% | 254.82% | 219.07% | 16117.53% |
| Selling, General & Admin | 6.46M | 10.83M | 9.64M | 13.98M | 20.01M | 25.68M | 20.64M | 26.88M | 22.34M |
| SG&A % of Revenue | 40400% | - | 3951.64% | 255.21% | 161.16% | 118.6% | 81.32% | 62.15% | 3997.14% |
| Research & Development | 7.94M | 9.74M | 13.34M | 20.21M | 30.77M | 43.55M | 44.02M | 67.88M | 67.75M |
| R&D % of Revenue | 49643.75% | - | 5465.57% | 368.84% | 247.81% | 201.11% | 173.5% | 156.93% | 12120.39% |
| Other Operating Expenses | 0 | 0 | 0 | 3.37M | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -14.39M▲ 0% | -20.57M▼ 42.9% | -22.73M▼ 10.5% | -35.85M▼ 57.7% | -45.81M▼ 27.8% | -61.04M▼ 33.2% | -49.6M▲ 18.7% | -63.32M▼ 27.6% | -89.75M▼ 41.7% |
| Operating Margin % | -89943.75% | - | -9317.21% | -654.26% | -369.02% | -281.87% | -195.48% | -146.38% | -16055.99% |
| Operating Income Growth % | -20.87% | -42.94% | -10.51% | -57.68% | -27.8% | -33.23% | 18.74% | -27.65% | -41.75% |
| EBITDA | -13.96M | -20.17M | -22.25M | -35.35M | -45.39M | -60.44M | -49.11M | -62.73M | -89.75M |
| EBITDA Margin % | -87237.5% | - | -9119.67% | -645.21% | -365.58% | -279.12% | -193.52% | -145% | -16055.99% |
| EBITDA Growth % | -20.37% | -44.52% | -10.31% | -58.87% | -28.39% | -33.17% | 18.76% | -27.74% | -43.09% |
| D&A (Non-Cash Add-back) | 433K | 399K | 482K | 496K | 427K | 596K | 498K | 593K | 0 |
| EBIT | -3.76M | -20.57M | -22.84M | -36.02M | -45.85M | -61.04M | -50.28M | -49.58M | 0 |
| Net Interest Income | -15K | 39K | -6K | 113K | 2K | 179K | 1.41M | 4.47M | 0 |
| Interest Income | 0 | 39K | 27K | 129K | 10K | 226K | 1.45M | 4.47M | 0 |
| Interest Expense | 15K | 0 | 33K | 16K | 8K | 47K | 34K | 0 | 0 |
| Other Income/Expense | 10.62M | 45K | -136K | -194K | -42K | 11.39M | -706K | 18.86M | 1.15M |
| Pretax Income | -3.77M▲ 0% | -20.53M▼ 443.7% | -22.87M▼ 11.4% | -36.04M▼ 57.6% | -45.86M▼ 27.2% | -49.65M▼ 8.3% | -50.31M▼ 1.3% | -44.46M▲ 11.6% | -88.6M▼ 99.3% |
| Pretax Margin % | -23593.75% | - | -9372.95% | -657.8% | -369.36% | -229.26% | -198.27% | -102.79% | -15849.91% |
| Income Tax | -2.16M | -2.12M | -3.29M | -3.49M | -6.45M | 688K | -7.04M | 845K | -11K |
| Effective Tax Rate % | 57.14% | 10.3% | 14.38% | 9.69% | 14.06% | -1.39% | 14% | -1.9% | 0.01% |
| Net Income | -1.62M▲ 0% | -18.41M▼ 1037.9% | -19.58M▼ 6.4% | -32.55M▼ 66.2% | -39.41M▼ 21.1% | -50.33M▼ 27.7% | -43.27M▲ 14.0% | -45.31M▼ 4.7% | -88.61M▼ 95.6% |
| Net Margin % | -10112.5% | - | -8025.41% | -594.03% | -317.44% | -232.44% | -170.51% | -104.74% | -15851.88% |
| Net Income Growth % | 80.83% | -1037.89% | -6.36% | -66.21% | -21.09% | -27.72% | 14.04% | -4.72% | -95.57% |
| Net Income (Continuing) | -1.62M | -18.41M | -19.58M | -32.55M | -39.41M | -50.33M | -43.27M | -45.31M | -88.61M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.07▲ 0% | -0.83▼ 1138.8% | -0.78▲ 6.0% | -1.11▼ 42.3% | -1.35▼ 21.6% | -3.78▼ 180.0% | -3.48▲ 7.9% | -2.37▲ 31.9% | -1.89▲ 20.3% |
| EPS Growth % | 83.25% | -1138.81% | 6.02% | -42.31% | -21.62% | -180% | 7.94% | 31.9% | 20.25% |
| EPS (Basic) | -0.07 | -0.83 | -0.78 | -1.11 | -1.35 | -3.78 | -3.48 | -2.37 | -1.89 |
| Diluted Shares Outstanding | 23.31M | 23.44M | 25.04M | 27.26M | 29.65M | 10.73M | 12.36M | 15.42M | 47.23M |
| Basic Shares Outstanding | 23.31M | 23.44M | 25.04M | 27.26M | 29.65M | 10.73M | 12.36M | 15.42M | 47.23M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
SLN Balance Sheet
Silence Therapeutics plc (SLN) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 45.55M | 29.5M | 37.47M | 76.4M | 86.33M | 96.69M | 103.15M | 187.37M | 118.66M |
| Cash & Short-Term Investments | 43.06M | 26.54M | 33.52M | 37.45M | 73.54M | 71.14M | 68.79M | 147.33M | 85.11M |
| Cash Only | 42.74M | 21.49M | 13.52M | 27.45M | 73.54M | 54.82M | 68.79M | 121.33M | 11.28M |
| Short-Term Investments | 319K | 5.04M | 20M | 10M | 0 | 16.33M | 0 | 26M | 73.84M |
| Accounts Receivable | 0 | 0 | 4K | 29.31M | 331K | 915K | 23.98M | 26.91M | 0 |
| Days Sales Outstanding | - | - | 5.98 | 1.95K | 9.73 | 15.42 | 344.89 | 227.04 | - |
| Inventory | -2.48M | -2.45M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 3.51M | 5.7M | 8.16M | 16.43M | 0 | 0 | 33.54M |
| Total Non-Current Assets | 9.46M | 9.39M | 8.61M | 9.57M | 9.86M | 10.81M | 16.3M | 15.27M | 12.78M |
| Property, Plant & Equipment | 1.17M | 921K | 611K | 1.13M | 1.94M | 2.2M | 2.31M | 1.98M | 1.75M |
| Fixed Asset Turnover | 0.01x | - | 0.40x | 4.86x | 6.39x | 9.84x | 10.99x | 21.90x | 0.32x |
| Goodwill | 8.03M | 8.13M | 7.69M | 8.13M | 7.59M | 8.01M | 9.98M | 9.39M | 10.62M |
| Intangible Assets | 28K | 64K | 34K | 17K | 24K | 320K | 362K | 312K | 288K |
| Long-Term Investments | 0 | -4.77M | 275K | 303K | 301K | 284K | 0 | 0 | 0 |
| Other Non-Current Assets | 233K | 5.04M | 0 | 0 | 0 | 0 | 3.65M | 3.59M | 127K |
| Total Assets | 55.01M▲ 0% | 38.88M▼ 29.3% | 46.08M▲ 18.5% | 85.97M▲ 86.6% | 96.19M▲ 11.9% | 107.5M▲ 11.8% | 119.45M▲ 11.1% | 202.63M▲ 69.6% | 131.44M▼ 35.1% |
| Asset Turnover | 0.00x | - | 0.01x | 0.06x | 0.13x | 0.20x | 0.21x | 0.21x | 0.00x |
| Asset Growth % | -1.41% | -29.31% | 18.5% | 86.58% | 11.89% | 11.75% | 11.11% | 69.64% | -35.13% |
| Total Current Liabilities | 2.66M | 3.83M | 9.65M | 25.57M | 15.17M | 21.94M | 22.34M | 16.82M | -13.61M |
| Accounts Payable | 462K | 1.15M | 1.79M | 2.29M | 4.07M | 3.19M | 3.35M | 3.7M | 0 |
| Days Payables Outstanding | 21.23 | 42.97 | - | 221.7 | 199 | 86.38 | 118.44 | 114.26 | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 228K | 0 | -89K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 6.57M | 306K | 0 |
| Other Current Liabilities | 0 | 27K | 2.48M | 17.04M | 4.43M | 9.45M | 8.58M | 3.44M | -13.52M |
| Current Ratio | 17.14x | 7.70x | 3.88x | 2.99x | 5.69x | 4.41x | 4.62x | 11.14x | - |
| Quick Ratio | 18.08x | 8.34x | 3.88x | 2.99x | 5.69x | 4.41x | 4.62x | 11.14x | - |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 462K | 1.15M | 15.52M | 51.34M | 72.5M | 63.48M | 75.12M | 51.79M | -71K |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -71K |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 118K | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 15.52M | 51.34M | 72.5M | 63.48M | 0 | 0 | 0 |
| Total Liabilities | 2.66M | 3.83M | 25.17M | 76.91M | 87.67M | 85.43M | 97.45M | 68.61M | -69.14M |
| Total Debt | 0 | 0 | 287K | 341K | 137K | 446K | 346K | 117K | -160K |
| Net Debt | -42.74M | -21.49M | -13.23M | -27.11M | -73.4M | -54.37M | -68.44M | -121.21M | -11.44M |
| Debt / Equity | - | - | 0.01x | 0.04x | 0.02x | 0.02x | 0.02x | 0.00x | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -959.40x | - | -688.91x | -2240.44x | -5726.75x | -1298.72x | -1458.94x | - | - |
| Total Equity | 52.35M▲ 0% | 35.05M▼ 33.0% | 20.91M▼ 40.4% | 9.06M▼ 56.7% | 8.53M▼ 5.9% | 22.07M▲ 158.9% | 21.99M▼ 0.4% | 134.02M▲ 509.4% | -62.3M▼ 146.5% |
| Equity Growth % | -3.38% | -33.04% | -40.35% | -56.67% | -5.88% | 158.88% | -0.36% | 509.39% | -146.49% |
| Book Value per Share | 2.25 | 1.50 | 0.83 | 0.33 | 0.29 | 2.06 | 1.78 | 8.69 | -1.32 |
| Total Shareholders' Equity | 52.35M | 35.05M | 20.91M | 9.06M | 8.53M | 22.07M | 21.99M | 134.02M | -62.3M |
| Common Stock | 3.5M | 3.55M | 3.92M | 4.17M | 4.49M | 5.39M | 8.85M | 10.29M | -10.29M |
| Retained Earnings | -116.43M | -133.78M | -152M | -184.22M | -222.97M | -263.26M | -431.89M | -474.04M | 562.57M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 165.28M | 165.28M | 30.84M | 35.38M | 42.67M | 53.27M | 40.36M | -11.78M | 2.98M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SLN Cash Flow Statement
Silence Therapeutics plc (SLN) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -9.6M | -16.76M | 1.73M | -10.78M | 9.19M | -57.04M | -39.35M | -67.64M | -62.27M |
| Operating CF Margin % | -59993.75% | - | 707.79% | -196.68% | 73.99% | -263.42% | -155.07% | -156.36% | -11139.71% |
| Operating CF Growth % | 4.64% | -74.6% | 110.3% | -723.97% | 185.24% | -721.01% | 31.02% | -71.89% | 7.94% |
| Net Income | -3.77M | -20.53M | -22.87M | -36.04M | -61.89M | -50.33M | -50.31M | -36.19M | -88.61M |
| Depreciation & Amortization | 433K | 399K | 482K | 496K | 576.29K | 596K | 498K | 593K | 312K |
| Stock-Based Compensation | 638K | 681K | 584K | 4.39M | 11.65M | 12.69M | 13.05M | 13.03M | 8.07M |
| Deferred Taxes | -8.4M | 1.82M | 2.31M | 3.02M | 5.95M | 688K | 0 | 845K | 0 |
| Other Non-Cash Items | -206K | -45K | 136K | -1.3M | 468.32K | -1.28M | 9.07M | -12.89M | 17.95M |
| Working Capital Changes | 1.71M | 913K | 21.09M | 18.66M | 52.43M | -19.4M | -11.66M | -33.02M | 0 |
| Change in Receivables | 664K | 691K | -4K | -29.3M | 37.09M | -10.54M | 314K | -904K | 1.02M |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Investing | 13.01M | -4.83M | -15.02M | 9.62M | 11.71M | -20.5M | 16.43M | -21.97M | -47.99M |
| Capital Expenditures | -173K | -188K | -9K | -511K | -1.77M | -173K | -45K | -211K | -55K |
| CapEx % of Revenue | 1081.25% | - | 3.69% | 9.33% | 14.25% | 0.8% | 0.18% | 0.49% | 9.84% |
| Acquisitions | -13.22M | -58K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 13.2M | 97K | -6K | 129K | -17.55K | -372K | 958K | 117.41M | 118.48M |
| Cash from Financing | 48K | 341K | 5.27M | 15.43M | 41.45M | 52.58M | 25.16M | 142.09M | 15K |
| Debt Issued (Net) | 0 | 0 | 0 | -402K | -284.77K | 0 | -174K | 0 | 0 |
| Equity Issued (Net) | 48K | 341K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 15K |
| Net Change in Cash | 3.73M▲ 0% | -21.25M▼ 669.3% | -7.98M▲ 62.5% | 13.93M▲ 274.6% | 62.2M▲ 346.4% | -33.08M▼ 153.2% | -785K▲ 97.6% | 52.54M▲ 6793.1% | -110.25M▼ 309.8% |
| Free Cash Flow | -9.77M▲ 0% | -16.95M▼ 73.4% | 1.72M▲ 110.1% | -11.29M▼ 757.2% | 7.39M▲ 165.4% | -57.59M▼ 879.8% | -39.4M▲ 31.6% | -67.85M▼ 72.2% | -62.33M▲ 8.1% |
| FCF Margin % | -61075% | - | 704.1% | -206.06% | 59.49% | -265.94% | -155.25% | -156.85% | -11149.55% |
| FCF Growth % | 7.84% | -73.43% | 110.14% | -757.16% | 165.41% | -879.79% | 31.59% | -72.23% | 8.14% |
| FCF per Share | -0.42 | -0.72 | 0.07 | -0.41 | 0.25 | -5.37 | -3.19 | -4.40 | -1.32 |
| FCF Conversion (FCF/Net Income) | 5.93x | 0.91x | -0.09x | 0.33x | -0.23x | 1.13x | 0.91x | 1.49x | 0.70x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 433K | 0 |
SLN Key Ratios
Silence Therapeutics plc (SLN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -14.73% | -3.04% | -42.13% | -69.98% | -217.21% | -448.22% | -329% | -196.38% | -58.08% | -247.11% |
| Return on Invested Capital (ROIC) | -75.38% | -87.12% | -133.2% | -160.54% | - | - | - | - | -370.72% | - |
| Gross Margin | -1031.3% | -49543.75% | - | 100% | 31.34% | 39.94% | 37.83% | 59.34% | 72.7% | 61.54% |
| Net Margin | -1096.1% | -10112.5% | - | -8025.41% | -594.03% | -317.44% | -232.44% | -170.51% | -104.74% | -15851.88% |
| Debt / Equity | - | - | - | 0.01x | 0.04x | 0.02x | 0.02x | 0.02x | 0.00x | - |
| Interest Coverage | - | -959.40x | - | -688.91x | -2240.44x | -5726.75x | -1298.72x | -1458.94x | - | - |
| FCF Conversion | 1.19x | 5.93x | 0.91x | -0.09x | 0.33x | -0.23x | 1.13x | 0.91x | 1.49x | 0.70x |
| Revenue Growth | - | -97.92% | -100% | - | 2145.49% | 126.59% | 74.43% | 17.18% | 70.47% | -98.71% |
SLN SEC Filings & Documents
Silence Therapeutics plc (SLN) SEC filings — annual & quarterly reports (10-K, 10-Q)
SLN Frequently Asked Questions
Silence Therapeutics plc (SLN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Silence Therapeutics plc (SLN) reported $0.6M in revenue for fiscal year 2025.
Silence Therapeutics plc (SLN) saw revenue decline by 98.7% over the past year.
Silence Therapeutics plc (SLN) reported a net loss of $88.6M for fiscal year 2025.
Dividend & Returns
Silence Therapeutics plc (SLN) has a return on equity (ROE) of -247.1%. Negative ROE indicates the company is unprofitable.
Silence Therapeutics plc (SLN) had negative free cash flow of $62.4M in fiscal year 2025, likely due to heavy capital investments.
Explore More SLN
Silence Therapeutics plc (SLN) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates